-
Mashup Score: 0The association between US Food and Drug Administration−expedited review designations and health plan specialty drug coverage - 2 year(s) ago
BACKGROUND: The US Food and Drug Administration (FDA) speeds approval of important clinical advancements through 4 expedited review programs: Priority Review, Accelerated Approval, Fast Track, and Breakthrough Therapy. Whether health plans prioritize coverage of expedited drugs relative to drugs that the FDA determined did not qualify from these programs is unclear. OBJECTIVES: To investigate how…
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review - 2 year(s) ago
BACKGROUND: Specialty drugs are identified by high monthly costs and complexity of administration. Payers use utilization management strategies, including prior authorization and separate tiers with higher cost sharing, to control spending. These strategies can negatively impact patients’ health outcomes through treatment initiation delays, medication abandonment, and nonadherence. OBJECTIVE: To…
Categories: Hem/Oncs, Latest HeadlinesTweet-
New article from @amcporg JMCP concludes that payer programs that reduce patient coast sharing increase initiation and persistence. Do you agree? https://t.co/rrIGTN0asw
-
-
Mashup Score: 0Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions - 2 year(s) ago
BACKGROUND: The Institute for Clinical and Economic Review (ICER) has emerged in a visible role in US health care. However, it is unclear to what extent US commercial health plans use ICER value assessments in their specialty drug coverage decisions. OBJECTIVE: To evaluate the relationship between ICER’s reported cost-effectiveness ratios (CERs) and coverage restrictiveness. Also, to examine the…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Examining US commercial health plans’ use of @icer_review ’s reports in specialty drug coverage decisions https://t.co/AwYYoMXzuo via @PeterNeumann11 et al @barttels2
-
-
Mashup Score: 2
Digital health tools, specifically digital therapeutics (DTx), which are primarily used to prevent, manage, and treat medical conditions, pose both challenges and opportunities to the health care system. To address needs related to coverage evaluation and access to DTx, AMCP held a virtual multistakeholder forum from August 31 to September 1, 2021. The group of 41 experts convened included…
Categories: Latest Headlines, PayerTweet-
From Aug. 31-Sept. 1, AMCP held a second Digital Therapeutics Partnership Forum where more than 40 experts convened virtually to discuss its evolving role in managed care pharmacy. Access the proceedings from the forum today: https://t.co/1I2COcdq38 #digitaltherapeutics https://t.co/smj77l46zV
-
New article from Journal of Managed Care and Specialty Pharmacy indicates that most health plans plans issued 62% (742/1,190) of policies within a year of a drug’s FDA approval. Surprised? Read more here: https://t.co/iTmlgg622S